According to a revised black box warning for capecitabine (Xeloda), patients should be tested for genetic variants of the DPYD gene prior to starting capecitabine unless immediate treatment is ...
or on the link below. On Oct. 3, 2025, the U.S. Food and Drug Administration approved a change to the Xeloda (brand name for capecitabine) label that revised the Black Box Warning to include the ...
“Using Panitumumab with metronomic Capecitabine is considered an accepted maintenance regimen in wild type Ras metastatic colorectal cancer regardless of the primary site” In this study, researchers ...
The FDA added a boxed warning to capecitabine and 5-FU labels, noting the risk of serious adverse reactions or death in patients with complete DPD deficiency. Capecitabine and 5-FU are both nucleoside ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial Patients were randomly ...
Evaluation of End-of-Life Quality Care Between American Indian and White North Carolina Decedents Diagnosed With Lung Cancer, 2003-2020 This is a single-institution retrospective study that included ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results